MX2019001769A - Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. - Google Patents
Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.Info
- Publication number
- MX2019001769A MX2019001769A MX2019001769A MX2019001769A MX2019001769A MX 2019001769 A MX2019001769 A MX 2019001769A MX 2019001769 A MX2019001769 A MX 2019001769A MX 2019001769 A MX2019001769 A MX 2019001769A MX 2019001769 A MX2019001769 A MX 2019001769A
- Authority
- MX
- Mexico
- Prior art keywords
- col6a3
- antigen
- antigen recognition
- same
- tcr
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 102100024338 Collagen alpha-3(VI) chain Human genes 0.000 abstract 4
- 101000909506 Homo sapiens Collagen alpha-3(VI) chain Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención pertenece a construcciones de reconocimiento de antígenos, en concreto de los antígenos de COL6A3. La invención proporciona en concreto moléculas basadas en un nuevo receptor de linfocitos T (TCR) que son selectivas y específicas hacia el antígeno tumoral COL6A3. El TCR de la invención, así como los fragmentos que se enlazan al antígeno de COL6A3 y que se derivan del mismo, están destinados al diagnóstico, el tratamiento y la prevención de las enfermedades cancerosas que expresan el COL6A3. Además se proporcionan ácidos nucleicos que codifican las construcciones de reconocimiento de antígenos de la invención, los vectores que comprenden esos ácidos nucleicos, las células recombinantes que expresan las construcciones de reconocimiento de antígenos y las composiciones farmacéuticas que comprenden los compuestos de la invención.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376059P | 2016-08-17 | 2016-08-17 | |
| DE102016115246.3A DE102016115246C5 (de) | 2016-08-17 | 2016-08-17 | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| US201662376632P | 2016-08-18 | 2016-08-18 | |
| PCT/EP2017/066630 WO2018033291A1 (en) | 2016-08-17 | 2017-07-04 | T cell receptors and immune therapy using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019001769A true MX2019001769A (es) | 2019-07-08 |
| MX395287B MX395287B (es) | 2025-03-25 |
Family
ID=60419980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001769A MX395287B (es) | 2016-08-17 | 2017-07-04 | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10550182B2 (es) |
| EP (1) | EP3500593B1 (es) |
| JP (2) | JP6964351B2 (es) |
| CN (1) | CN109563149A (es) |
| AU (2) | AU2017312361B2 (es) |
| BR (1) | BR112019001922A2 (es) |
| CA (1) | CA3031995A1 (es) |
| CR (1) | CR20190095A (es) |
| DE (1) | DE102016115246C5 (es) |
| DK (1) | DK3500593T3 (es) |
| LT (1) | LT3500593T (es) |
| MA (1) | MA45976B1 (es) |
| MX (1) | MX395287B (es) |
| PE (1) | PE20190477A1 (es) |
| RS (1) | RS62498B1 (es) |
| SG (1) | SG11201900955VA (es) |
| TW (1) | TWI775768B (es) |
| WO (1) | WO2018033291A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| ZA201900664B (en) * | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
| JP7037577B2 (ja) * | 2017-03-15 | 2022-03-16 | フレッド ハッチンソン キャンサー リサーチ センター | 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 |
| WO2019046818A1 (en) | 2017-09-01 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER |
| DE102017125888A1 (de) | 2017-11-06 | 2019-05-23 | Immatics Biotechnologies Gmbh | Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie |
| MY203553A (en) | 2017-11-06 | 2024-07-03 | Immatics Biotechnologies Gmbh | Novel engineered t cell receptors and immune therapy using the same |
| EP3749753B1 (en) | 2018-02-09 | 2025-04-02 | Immatics US, Inc. | Methods for manufacturing t cells |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CN112292037B (zh) | 2018-06-19 | 2024-03-22 | 帝斯曼知识产权资产管理有限公司 | 脂解酶变体 |
| CA3127096A1 (en) * | 2019-01-22 | 2020-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted t cell receptors against ras with g12r mutation |
| US12448429B2 (en) | 2019-03-06 | 2025-10-21 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| CA3141505A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| ES2991645T3 (es) | 2019-06-06 | 2024-12-04 | Immatics Biotechnologies Gmbh | Clasificación con contraselección mediante péptidos de secuencia similar |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CN115427554A (zh) | 2020-02-24 | 2022-12-02 | 伊玛提克斯美国公司 | 扩增t细胞治疗癌症和相关恶性肿瘤的方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20230227526A1 (en) * | 2020-06-09 | 2023-07-20 | Board Of Regents, The University Of Texas System | Engineered t cell receptors and methods of use |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| KR20230135589A (ko) | 2020-12-31 | 2023-09-25 | 이매틱스 유에스 인코포레이티드 | Cd8 폴리펩타이드, 조성물 및 이의 사용 방법 |
| EP4334350A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Bma031 antigen binding polypeptides |
| EP4392441A1 (en) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| WO2023056240A2 (en) | 2021-09-28 | 2023-04-06 | Frontaim Biomedicines, Inc. | Multiple formats of molecular complexes |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN116813744B (zh) * | 2023-02-23 | 2024-02-23 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN120718134B (zh) * | 2025-08-25 | 2025-12-26 | 北京立康生命科技有限公司 | 靶向col6a3肽的t细胞受体及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US7820401B2 (en) * | 2004-08-23 | 2010-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Collagen VI and cancer |
| EP1762575A1 (en) * | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| US8105831B2 (en) * | 2007-03-09 | 2012-01-31 | University Of Washington | Parvoviral production of HLA homozygous cells |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US9228007B1 (en) * | 2010-03-11 | 2016-01-05 | The Regents Of The University Of California | Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| CA2918216C (en) * | 2013-07-15 | 2023-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human papillomavirus 16 e6 t cell receptors |
| AU2015289644A1 (en) * | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| AU2015342964B2 (en) * | 2014-11-05 | 2021-06-24 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
-
2016
- 2016-08-17 DE DE102016115246.3A patent/DE102016115246C5/de not_active Expired - Fee Related
-
2017
- 2017-07-04 JP JP2019508259A patent/JP6964351B2/ja active Active
- 2017-07-04 LT LTEPPCT/EP2017/066630T patent/LT3500593T/lt unknown
- 2017-07-04 RS RS20211327A patent/RS62498B1/sr unknown
- 2017-07-04 SG SG11201900955VA patent/SG11201900955VA/en unknown
- 2017-07-04 PE PE2019000285A patent/PE20190477A1/es unknown
- 2017-07-04 DK DK17739220.6T patent/DK3500593T3/da active
- 2017-07-04 CR CR20190095A patent/CR20190095A/es unknown
- 2017-07-04 MX MX2019001769A patent/MX395287B/es unknown
- 2017-07-04 MA MA45976A patent/MA45976B1/fr unknown
- 2017-07-04 CA CA3031995A patent/CA3031995A1/en active Pending
- 2017-07-04 CN CN201780049787.2A patent/CN109563149A/zh active Pending
- 2017-07-04 EP EP17739220.6A patent/EP3500593B1/en active Active
- 2017-07-04 BR BR112019001922A patent/BR112019001922A2/pt not_active IP Right Cessation
- 2017-07-04 AU AU2017312361A patent/AU2017312361B2/en not_active Ceased
- 2017-07-04 WO PCT/EP2017/066630 patent/WO2018033291A1/en not_active Ceased
- 2017-08-11 TW TW106127257A patent/TWI775768B/zh not_active IP Right Cessation
- 2017-08-15 US US15/677,651 patent/US10550182B2/en not_active Expired - Fee Related
-
2018
- 2018-07-13 US US16/035,300 patent/US10526407B2/en active Active
-
2021
- 2021-03-10 AU AU2021201518A patent/AU2021201518A1/en not_active Abandoned
- 2021-08-04 JP JP2021128303A patent/JP2021184729A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20190095A (es) | 2019-06-13 |
| JP2021184729A (ja) | 2021-12-09 |
| CA3031995A1 (en) | 2018-02-22 |
| CN109563149A (zh) | 2019-04-02 |
| LT3500593T (lt) | 2021-11-25 |
| AU2017312361B2 (en) | 2020-12-10 |
| MA45976A (fr) | 2021-05-19 |
| PE20190477A1 (es) | 2019-04-04 |
| MA45976B1 (fr) | 2021-09-30 |
| AU2017312361A1 (en) | 2019-02-28 |
| DK3500593T3 (da) | 2021-11-01 |
| DE102016115246B3 (de) | 2017-12-14 |
| US10526407B2 (en) | 2020-01-07 |
| DE102016115246C5 (de) | 2018-12-20 |
| JP6964351B2 (ja) | 2021-11-10 |
| AU2021201518A1 (en) | 2021-04-01 |
| WO2018033291A1 (en) | 2018-02-22 |
| SG11201900955VA (en) | 2019-03-28 |
| EP3500593B1 (en) | 2021-08-25 |
| US20180319884A1 (en) | 2018-11-08 |
| JP2019528061A (ja) | 2019-10-10 |
| TWI775768B (zh) | 2022-09-01 |
| BR112019001922A2 (pt) | 2019-07-09 |
| RS62498B1 (sr) | 2021-11-30 |
| US20180051080A1 (en) | 2018-02-22 |
| TW201806973A (zh) | 2018-03-01 |
| US10550182B2 (en) | 2020-02-04 |
| MX395287B (es) | 2025-03-25 |
| EP3500593A1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001769A (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| MX2020004741A (es) | Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos. | |
| CO2019011688A2 (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra cánceres positivos para prame | |
| MX2019015742A (es) | Receptores de celulas t novedosos, e inmunoterapia usando los mismos. | |
| MX2019006724A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| MX2022015821A (es) | Nuevos receptores de celulas t y usos de los mismos. | |
| CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
| CL2019000366A1 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| MX2018002480A (es) | Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer. | |
| MX2018005273A (es) | Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de mama y otos tipos de cancer. | |
| MX2017017145A (es) | Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres. | |
| MX2017012427A (es) | Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores. | |
| MX2017017148A (es) | Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra cancer esofagico y otros canceres. | |
| AR113834A1 (es) | Receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos | |
| CO2019002229A2 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos | |
| EA202090712A1 (ru) | Новые полученные методами генной инженерии t-клеточные рецепторы и иммунная терапия с их использованием | |
| AR109345A1 (es) | Receptores de linfocitos t e inmunoterapia basada en el uso de los mismos | |
| AR110682A1 (es) | Receptores de células t y terapia inmunológica que los utiliza | |
| CO2019006926A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
| EA201990488A1 (ru) | Новые t-клеточные рецепторы и иммунотерапия с их применением | |
| EA201992002A1 (ru) | Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением |